GSK Presents Data Showing Combo Therapy Eased Flares in COPD Patients at Risk of CVD

GlaxoSmithKline (GSK) recently presented new data from a pre-specified analysis of the SUMMIT clinical trial, showing that once daily treatment with  Breo Ellipta (fluticasone furoate/vilanterol) reduced exacerbations in chronic obstructive pulmonary disease (COPD) patients compared to placebo. The presentation was one of two given at the American Thoracic Society (ATS) 2016 International…

Positive Phase 3b Data for COPD Therapy Anoro Ellipta Presented by GSK

GlaxoSmithKline (GSK) and Innoviva presented positive  results from a Phase 3b study investigating the efficacy and safety of Anoro Ellipta (umeclidinium/vilanterol, or  UMEC/VI) in patients with moderate chronic obstructive pulmonary disease (COPD) who continued to experience symptoms while on tiotropium (bronchodilator) monotherapy. Anoro Ellipta is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting…

AstraZeneca Highlights Respiratory Medicines at ATS 2016

AstraZeneca is presenting a broad selection of its novel respiratory disease medicines through more than 60 abstracts and scientific presentations at the American Thoracic Society (ATS) 2016 International Conference through May 18 in San Francisco, Calif. Presentations highlight combinations, respiratory biologics, and scientific research projects that target new pathways…

Sunovion to Present New Clinical Data on Brovana, a COPD Inhalation Therapy, at ATS 2016

Sunovion Pharmaceuticals, Inc., will present new clinical and health outcomes data for its Brovana (arformoterol tartrate) Inhalation Solution at the 2016 American Thoracic Society International Conference (ATS 2016), taking place May 13–18 in San Francisco, California. At the ATS meeting, Sunovion will present post-hoc analyses of clinical data generated from its…